Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2729430
Reference Type
Journal Article
Title
Ibopamine in congestive heart failure refractory to digitalis, diuretics, and captopril
Author(s)
Marchionni, N; Conti, A; De Alfieri, W; Di Bari, M; Vannucci, A; Et al
Year
1986
Is Peer Reviewed?
Yes
Journal
Journal of Clinical Pharmacology
ISSN:
0091-2700
EISSN:
1552-4604
Report Number
IPA/86/690019
Volume
Clin
Issue
REF 6
Page Numbers
74-77
Language
English
Abstract
IPA COPYRIGHT: ASHP The efficacy of oral ibopamine (I) given in a dose of 1.25 mg/kg, was assessed in 6 patients (aged 48-67 yr) with congestive heart failure refractory to daily treatment with 0.125-0.250 mg digoxin (II), 25-250 mg furosemide (III), and 25 mg captopril (IV), 3-4 times a day; the patients were maintained on therapy with all 4 drugs and followed up for about 3 months. The hemodynamic improvement induced by I was relatively modest. The stroke index to mean pulmonary capillary wedge pressure ratio rose only from a basal level of 29% of the lower limit of normal to 32% at the time of effect of I. A greater enhancement to 39% of normal was gained with the addition of IV, suggesting some advantage in using vasodilators in conjunction with I to obtain more hemodynamic improvement and to prevent possible increase in pulmonary pressures. Five of 6 patients experienced increasing dyspnea after I dosing which disappeared on I discontinuation and evidence of liver toxicity was evident in one patient.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity